Natco Pharma Limited has informed the Exchange regarding a press release dated May 17, 2021, titled "NATCO signs Voluntary Licensing Agreement with Lilly for Baricitinib for Covid-19 in India ".
Press Release May 17 2021
Filed with NSE ·
6ix hasn’t read this filing yet.
Earlier from NATCO Pharma
- Press Release May 03 2021
- Press Release Apr 26 2021
- NATCO Pharma receives tentative approval for Ibrutinib tablets (generic for IMBRUVICA) ANDA in the US market
- Press Release Apr 10 2021
- NATCO Pharma forays into Pheromone based technology for Integrated Pest Management
Later from NATCO Pharma
- Press Release May 21 2021
- Press Release May 22 2021
- Press Release Jun 14 2021
- Press Release Jul 07 2021
- Press Release Aug 03 2021
Follow NATCO Pharma into a list and get an email when it puts out news.
Follow NATCO Pharma